Navigation Links
Genetically Modified Natural Killer Immune Cells Attack, Kill Leukemia Cells

Natural killer (NK) immune system cells can be genetically modified to brandish a powerful "on-switch" that prompts them to aggressively attack and kill leukemic cells. This finding, from researchers at St. Jude Children's Research Hospital, suggests a way to improve the outcome of children who receive treatment for acute lymphoblastic leukemia (ALL) or other blood cancers.

Results of the St. Jude study are published in the current online issue of Blood.

The researchers demonstrated how to overcome significant technical hurdles that have until now slowed development of NK-based therapies for ALL, according to Dario Campana, M.D., Ph.D., a member of St. Jude Hematology-Oncology and Pathology, and senior author of the Blood report. Progress in adapting NK cells to the treatment of ALL had been significantly hampered because researchers were not able to grow large numbers of these immune cells in the laboratory, and because NK cells normally have only weak anti-leukemic activity.

The key breakthroughs made by the St. Jude team were the development of a laboratory technique for rapidly producing a large, pure population of NK cells from a small sample of blood; and developing a technique for genetically modifying NK cells so that they would become potent killers when they encountered leukemic cells.

In order to grow large populations of NK cells, the team started with samples of blood containing a variety of different immune system cells. They placed this sample into a dish containing a type of human leukemia cell called K562. Campana's team genetically modified the K562 cells so they carried on their surfaces many copies of two different proteins, 4-1BBL and IL-15. The genetically modified K562 cells quickly stimulated the expansion of the NK cell population to more than10,000 times their original number. The technique triggered growth of NK cells specifically, which greatly simplified the ability of the researchers to collect a pure popu lation of these immune cells.

The researchers then genetically modified the growing NK cells so they carried on their surface an artificial receptor that made them particularly aggressive and effective killers that attacked only leukemic cells. A receptor is a protein that binds to a specific target molecule. The artificial receptor on the NK molecule was designed to recognize a protein called CD19, which is found on the surface of leukemic cells. When the receptor bound to CD19 on leukemic cells, it set off a reaction that super-charged the killing activity of the NK cell.

"By developing a technique for cultivating large numbers of NK cells from a small blood sample, we made it practical to consider them a potential treatment against many different types of cancer," Campana said. "By genetically modifying NK cells so they expressed the CD19 receptor, we made them specifically effective against ALL cells."

A potential clinical application for the technology developed in this study is in leukemia patients who are treated with hematopoietic (blood cell-forming) cell transplantation. In this case, NK cells will be derived from the transplant donor, expanded and genetically modified. These modified NK cells will then be infused into the patient after the transplant in order to eliminate residual leukemic cells. In another application, NK cells could be obtained from a patient while in remission and then reinfused after genetic modification if the patient suffers a resurgence of the leukemia.

"We look forward to seeing this strategy being added to the management of children with ALL," said Chihaya Imai, M.D., the postdoctoral student who did most of the work on this project.


'"/>

Source:St. Jude Children's Research Hospital


Related biology news :

1. Genetically modified natural killer immune cells attack, kill leukemia cells
2. Genetically modified rice in China benefits farmers health, study finds
3. Genetically engineered animals help in scientific research that may benefit children
4. Genetically modified maize not found in southern Mexico
5. Genetically engineered mosquitoes show resistance to dengue fever virus
6. Genetically altered mice no longer like cocaine
7. Genetically engineered blood protein can be used to split water into oxygen and hydrogen
8. Modified collagen could yield important medical applications
9. Natural Killers Could Lead to New Hepatitis Treatments
10. Natural tumor suppressor in body discovered by UCSD medical researchers
11. Naturally occurring asbestos linked to lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2017)... NEW YORK , Feb. 8, 2017 /PRNewswire/ ... an individual,s voice to match it against a ... voice such as pitch, cadence, and tone are ... systems require minimal hardware installation, as most PCs ... remotely for different transactions. Voice recognition biometrics are ...
(Date:2/8/2017)... 2017 Report Highlights ... The global synthetic-biology market reached nearly ... 2021, growing at a compound annual growth rate (CAGR) of ... the global markets for synthetic biology. - Analyses of global ... projections of compound annual growth rates (CAGRs) through 2021. - ...
(Date:2/8/2017)... -- Report Highlights The global biosurgery market ... in 2016 at a compound annual growth rate (CAGR) ... - An overview of the global market for biosurgery. ... 2015 and 2016, and projections of compound annual growth ... on the basis of product type, source, application, and ...
Breaking Biology News(10 mins):
(Date:2/20/2017)...  At the 2017 Health Information Management Systems ... , IBM (NYSE: IBM ) today introduced ... President and CEO Ginni Rometty will ... 8:30-10 am ET, broadcast live on www.ibm.com ... examine the advent of the Cognitive Era and ...
(Date:2/18/2017)... 2017 Kurzlehrgang mit Fokus ... Zelltherapie-Studien, Poster legt metaproteomische Analyse des Darm-Mikrobioms bei Säuglingen ... ... Dr. Yoav Peretz , Scientific Director bei ImmuneCarta, ... Assays zum Nachweis intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien im ...
(Date:2/18/2017)... DUBLIN , Feb 17, 2017 Research ... Global Strategic Business Report" report to their offering. ... The report provides separate ... Europe , and Rest of World. Annual estimates and ... six-year historic analysis is provided for these markets. Market data and ...
(Date:2/17/2017)... 17, 2017  If only one in every ... mutation-conferring resistance to chemotherapy, thousands of cancer cells ... focused on finding these mutations in ever-smaller subpopulations ... tumor DNA in blood — to guide treatment ... Unfortunately, however, detecting these genetic anomalies may ...
Breaking Biology Technology: